Text Size

Cost-Utility Analysis of STN1013001, a Latanoprost Cationic Emulsion, versus Other Latanoprost Formulations (Latanoprost) in Open-Angle Glaucoma or Ocular Hypertension and Ocular Surface Disease in France

Lazzaro C., Van Steen C., Aptel F., Schweitzer C., Angelillo L.


  • 2022
  • Journal of Ophthalmology
View publication
  • Therapeutic Area

    Glaucoma

  • Affiliations

    Studio di Economia Sanitaria, Milan, Italy; Santen GmbH, München, Germany; Department of Ophthalmology, University Hospital, CHU Grenoble-Alpes, Grenoble, France; CHU Bordeaux, Department of Ophthalmology, University of Bordeaux, Bordeaux, 33000, France; Inserm, Bordeaux Population Health Research Center, Team LEHA, UMR 1219, Bordeaux, 33000, France

Related Publications

Felodipine re-positioned as a neuroprotectant via improved optic nerve head blood circulation in retinal ischemic rabbits and ocular hypertensive rats

Taniguchi T, Akaishi T, Hata T, Yamashita R, Esaki Y, Morofuji R, Okabe K, Fuwa M, Yamamoto Y, Guo L, Choi S, Luong V, Ota T, Sharif NA, Cordeiro MF, Kageyama M.


A Study of 24-h Efficacy and Safety of Sepetaprost vs. Latanoprost in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension

Konstas A.G.; Garhöfer G.; Lübke Y.; Voykov B.; Ropo A.


Valproic Acid Application to Modify Post Surgical Fibrosis in a Model of Minimally Invasive Bleb Surgery

Lo P.F.; Gunawan M.; Yap Z.L.; Leong C.; Kwek F.; Varadarajan J.; Wang X.; Kageyama M.; Wong T.T.


Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022